0 rating

New Oral Anticoagulants: Targeted Inhibition of Factor Xa and Thrombin

Antonio Ciaccia, MSc1, John Thai, BSc1, and Alexander GG Turpie, MD2

Anticoagulants are recommended for the prevention and treatment of a wide spectrum of thromboembolic disorders. Recent developments in antithrombotic therapy have the potential to significantly impact the management of patients. Several direct thrombin and Factor Xa inhibitors are under development, the most advanced of which are the direct thrombin inhibitor, dabigatran, and the direct Factor Xa inhibitors, apixaban and rivaroxaban. These new oral agents have shown considerable promise and may result in a paradigm shift in the management of thromboembolic disease. This article reviews the ongoing and completed trials of the various oral direct thrombin and Factor Xa inhibitors. Adv Orthop 2010;2(2):52–61.

Return to top

LATEST ARTICLES

Our most popular articles